ALK-POSITIVE NSCLC
Clinical trials for ALK-POSITIVE NSCLC explained in plain language.
Never miss a new study
Get alerted when new ALK-POSITIVE NSCLC trials appear
Sign up with your email to follow new studies for ALK-POSITIVE NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail targets tough lung cancer
Disease control OngoingThis study tests the safety and effectiveness of combining two drugs, ceritinib and nivolumab, in adults with a specific type of advanced lung cancer called ALK-positive NSCLC. About 57 participants will receive the drug combination to find the best dose and see if tumors shrink.…
Matched conditions: ALK-POSITIVE NSCLC
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
Lung cancer drug under the microscope: how does lorlatinib perform outside clinical trials?
Knowledge-focused OngoingThis study looks at how well the lung cancer medicine lorlatinib works when used as the first treatment for people with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer). Researchers will review medical records from a U.S. database to track how lon…
Matched conditions: ALK-POSITIVE NSCLC
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated May 19, 2026 11:59 UTC